The aim of this study is to evaluate the clinical and cost effectiveness of Dialectical Behavior Therapy (DBT) for chronically suicidal behavior in individuals diagnosed with borderline personality disorder (BPD). Recent investigations of DBT have yielded positive results and have challenged the widely held opinion that the prognosis for this condition is poor. This study will consist of a two-arm randomized controlled trial that will compare DBT with a General Psychiatric Management (GPM) condition consisting of a structured algorithmic medication intervention plus psychosocial counseling. One-hundred and eighty participants will be randomly assigned to either DBT or to the GPM condition. Clinical outcomes will be assessed by changes in: (1) parasuicidal behaviour; (2) treatment retention; (3) psychiatric symptomatology; (4) anger expression; (5) social functioning and (6) health status. Cost outcomes will include an analysis of health service utilization. Clinical and cost evaluations will occur at 4-month intervals over the course of the one-year treatment and over a two-year follow-up.

Condition	Intervention	Phase
Borderline Personality Disorder	Behavior: Dialectical Behavior Therapy & General Psychiatric Management	Phase III

Further Study Details: 

Primary Outcomes: Parasuicidal behaviour
Secondary Outcomes: Psychiatric hospitalization; Psychiatric symptoms; Anger; Treatment retention; Social functioning
Expected Total Enrollment:  180

Suicide, a major cause of death worldwide, is a serious public health problem. Forty percent of individuals who commit suicide meet diagnostic criteria for a personality disorder and an even higher percent of those attempting suicide have a personality disorder . Borderline personality disorder (BPD) is highly associated with parasuicidal behaviour. Parasuicidal behaviour refers to suicide attempts or other self-injurious behaviour and is a risk factor for completed suicide. Approximately 69% - 80% of people diagnosed with BPD have committed at least one act of self-harm. Estimates of completed suicides in this population are about 9%, with this rate quadrupling for patients who meet 8 or more of the 9 DSM criteria for BPD.

Chronically suicidal behaviour in people with BPD is estimated to be among the most expensive psychiatric disorders to treat. While there is an extensive anecdotal literature on the treatment of this population, clinical outcomes have been dismal and treatment evidence based on well-designed trials is sparse. Dialectical Behavior Therapy (DBT), a broad-based cognitive-behavioral therapy (CBT), has recently shown promise in the treatment of this population. DBT is being widely adopted in the treatment of this disorder despite its limited empirical base. To date, there are few studies on DBT and no replications of the original research on DBT by researchers independent of the treatment developer.

The aim of this study is to evaluate the clinical and cost effectiveness of DBT for the treatment of parasuicidal individuals with BPD compared to a General Psychiatric Management (GPM) control condition involving a structured algorithm medication intervention plus psychosocial support. This study will compare the following outcome measures in participants who receive Dialectical Behavior Therapy versus General Psychiatric Management, Best Practices during a one-year treatment interval and two-year follow-up: (1) frequency and severity of parasuicidal behaviours ; (2) number of self-harm episodes (3) improvement in quality of life (4) cost effectiveness.

Hypotheses:(1) Patients in the DBT condition will show greater reductions in the frequency and severity of parasuicidal behaviours compared to patients in the GPM condition during a one-year treatment interval and two-year follow-up; (2) Compared to GPM, DBT will result in a greater reduction in the number of self-harm episodes and a greater improvement in quality of life but will have a higher direct cost. However, because DBT will result in significant offsetting reductions in other health service costs, the incremental cost-effectiveness ratios will fall within the range of many accepted medical interventions.

Ages Eligible for Study:  18 Years   -   60 Years,  Genders Eligible for Study:  Both

Accepts Healthy Volunteers

Criteria

Inclusion Criteria:

• Meet DSM-IV criteria for BPD
• Between 18-60 years of age
• Have had two parasuicide episodes in the past five years with one occurring in the past 3 months
• Have had OHIP coverage for 1 year or more
• Literate in English
• Provide informed consent to participate in the study

Exclusion Criteria:

• Current active substance dependence disorder
• Psychotic disorder,bipolar I disorder, or dementia
• Evidence of an organic brain syndrome or mental retardation
• A chronic or serious physical health problem that will require hospitalization within the next year (e.g. cancer)
• A medical condition that would preclude the psychiatric medication regimen in the GPM condition
• Definite plans to leave the province in the next 2 years
• Currently engaged in DBT or GPM at St. Michael’s Hospital

Please refer to this study by ClinicalTrials.gov identifier  NCT00154154

Shelley F. McMain, PhD      416 535 8501  Ext. 6852    shelley_mcmain@camh.net
Eleanor J. Liu, PhD      416 535 8501  Ext. 6281    eleanor_liu@camh.net

Canada, Ontario
      Centre for Addiction and Mental Health, Toronto,  Ontario,  M5S 2S1,  Canada; Recruiting
      St Michael''''s Hospital, Toronto,  Ontario,  M5B 1W8,  Canada; Recruiting

Study chairs or principal investigators

Shelley F. McMain, PhD,  Principal Investigator,  Centre for Addiction and Mental Health   

Study ID Numbers:  CIHR: #200204MCT-101123; CIHR: #200204MCT-101123
Last Updated:  September 9, 2005
Record first received:  September 7, 2005
ClinicalTrials.gov Identifier:  NCT00154154
Health Authority: Canada: Health Canada
ClinicalTrials.gov processed this record on 2005-09-13